In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates

ABSTRACT The in vitro activity of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, was tested against 2,440 clinical isolates. Nemonoxacin was at least fourfold more active than levofloxacin and moxifloxacin against most gram-positive cocci tested (shown by the following MIC90/range [μg/ml] values; community-associated methicillin [meticillin]-resistant Staphylococcus aureus, 0.5/0.015 to 2; Staphylococcus epidermidis, 0.5/0.015 to 4 for methicillin-susceptible staphylococci and 2/0.12 to 2 for methicillin-resistant staphylococci; Streptococcus pneumoniae, 0.015/≤0.008 to 0.25; Enterococcus faecalis, 1/0.03 to 128). Nemonoxacin activity against gram-negative bacilli was similar to levofloxacin and moxifloxacin (MIC90/range [μg/ml]; Escherichia coli, 32/≤0.015 to ≥512; Klebsiella pneumoniae, 2/≤0.015 to 128; K. oxytoca, 0.5/0.06 to 1; Proteus mirabilis, 16/0.25 to ≥512; Pseudomonas aeruginosa, 32/≤0.015 to ≥512; Acinetobacter baumannii, 1/0.12 to 16).

Download Full-text

Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa

European Journal of Clinical Microbiology & Infectious Diseases ◽

10.1007/s10096-018-3221-y ◽

2018 ◽

Vol 37 (6) ◽

pp. 1091-1098 ◽

Cited By ~ 2

Author(s):

Manuel Kussmann ◽

Stefan Hauer ◽

Petra Pichler ◽

Gottfried Reznicek ◽

Heinz Burgmann ◽

...

Keyword(s):

Escherichia Coli ◽

Staphylococcus Aureus ◽

Pseudomonas Aeruginosa ◽

Peritoneal Dialysis ◽

Staphylococcus Epidermidis ◽

Vitro Activity ◽

In Vitro Activity ◽

Dialysis Fluids

Download Full-text

Determining Linezolid’s Baseline In Vitro Activity in Canada Using Gram-Positive Clinical Isolates Collected prior to Its National Release

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.46.6.1989-1992.2002 ◽

2002 ◽

Vol 46 (6) ◽

pp. 1989-1992 ◽

Cited By ~ 1

Author(s):

James A. Karlowsky ◽

Laurie J. Kelly ◽

Ian A. Critchley ◽

Mark E. Jones ◽

Clyde Thornsberry ◽

...

Keyword(s):

Staphylococcus Aureus ◽

Streptococcus Pneumoniae ◽

Staphylococcus Epidermidis ◽

Vitro Activity ◽

Clinical Isolates ◽

Clinical Use ◽

In Vitro Activity ◽

Gram Positive ◽

Future Studies

ABSTRACT All of the isolates of Staphylococcus aureus (n = 317), Enterococcus species (n = 315), Streptococcus pneumoniae (n = 282), and Staphylococcus epidermidis (n = 176) collected at 16 Canadian microbiology laboratories from October 2000 to April 2001 were susceptible to linezolid. Future studies will determine how linezolid clinical use in Canada affects its in vitro activity.

Download Full-text

In Vitro Activity of API-1252, a Novel FabI Inhibitor, against Clinical Isolates of Staphylococcus aureus and Staphylococcus epidermidis

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.01254-06 ◽

2007 ◽

Vol 51 (4) ◽

pp. 1580-1581 ◽

Cited By ~ 38

Author(s):

James A. Karlowsky ◽

Nancy M. Laing ◽

Nachum Kaplan ◽

Daryl J. Hoban ◽

George G. Zhanel ◽

...

Keyword(s):

Staphylococcus Aureus ◽

Staphylococcus Epidermidis ◽

Vitro Activity ◽

Clinical Isolates ◽

In Vitro Activity

Download Full-text

In Vitro Activity of Colistin (Polymyxin E) against 3,480 Isolates of Gram-Negative Bacilli Obtained from Patients in Canadian Hospitals in the CANWARD Study, 2007-2008

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.00786-09 ◽

2009 ◽

Vol 53 (11) ◽

pp. 4924-4926 ◽

Cited By ~ 42

Author(s):

A. Walkty ◽

M. DeCorby ◽

K. Nichol ◽

J. A. Karlowsky ◽

D. J. Hoban ◽

...

Keyword(s):

Escherichia Coli ◽

Pseudomonas Aeruginosa ◽

Acinetobacter Baumannii ◽

Multidrug Resistant ◽

Vitro Activity ◽

In Vitro Activity ◽

Broth Microdilution ◽

Gram Negative ◽

Polymyxin E

ABSTRACT The in vitro activity of colistin was evaluated versus 3,480 isolates of gram-negative bacilli using CLSI broth microdilution methods. The MIC90 of colistin was ≤2 μg/ml against a variety of clinically important gram-negative bacilli, including Escherichia coli, Klebsiella spp., Enterobacter spp., Acinetobacter baumannii, and Pseudomonas aeruginosa. All multidrug-resistant (n = 76) P. aeruginosa isolates were susceptible to colistin (MIC, ≤2 μg/ml). These data support a role for colistin in the treatment of infections caused by multidrug-resistant P. aeruginosa.

Download Full-text